Navigation Links
Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
Date:8/30/2012

RICHMOND, Calif., Aug. 30, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that Edward Lanphier, Sangamo's president and CEO, will provide an update on the progress of Sangamo's ZFP Therapeutic® development programs and an overview of the company's business strategy at 3:50 pm ET on Thursday, September 6, 2012, at the Stifel Nicolaus Healthcare Conference which will be held in New York City.

The presentation will be webcast live and may be accessed via a link on the Sangamo BioSciences website in the Investor Relations section http://investor.sangamo.com/index.cfm under Events and Presentations. The presentation will be archived on the Sangamo website for two weeks after the event.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia and  hemoglobinopathies such as sickle cell anemia and beta-thalassemia, and a program in Huntington's disease. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
2. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
3. Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
4. Sangamo BioSciences Reports First Quarter 2012 Financial Results
5. Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast
6. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
7. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
8. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
9. Neurocrine Biosciences Reports Second Quarter 2012 Results
10. Amarantus BioSciences Corporate Overview to be Webcast Live Today from OneMedForum 2012 Conference in NYC
11. Pressure BioSciences, Inc. Continues Global Sales Reach Expansion with Distribution Agreements for China, Vietnam, Laos, Cambodia, Australia, and New Zealand
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... -- Non-profit Consortium Aims to Generate Genomic Information ... and Discovery --> --> ... to sequence 100,000 individuals. It is intended to initially include ... of North and East Asian countries. --> ... will focus on creating phased reference genomes for all major ...
(Date:2/11/2016)... 11, 2016  Bioethics International, a not-for-profit organization focused on ... marketed and made accessible to patients around the world, today ... named the publication of the Good Pharma Scorecard ... also featured as one of BMJ Open ,s ,Most ... that are most frequently read. Ed Sucksmith , ...
(Date:2/11/2016)... Calif. , Feb. 11, 2016  Dovetail Genomics™ ... to its beta program for a planned metagenomic genome ... present the company,s metagenomic genome assembly method in a ... in Genome Biology & Technology conference in ... of these highly complex datasets is difficult. Using its ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... has announced a new agreement with Bankok,Thailand-based Global Stem Cells Network (GSCN) to ... in 15 Latin American countries, including Mexico, Costa Rica, Dominican Republic, Colombia, Argentina, ...
Breaking Biology Technology:
(Date:2/2/2016)... Technology Enhancements Accelerate Growth of X-ray Imaging ... and computed radiography markets in Thailand ... Indonesia (TIM). It provides an in-depth analysis ... as regional market drivers and restraints. The study offers ... market attractiveness, both for digital and computed radiography. Market ...
(Date:2/1/2016)... YORK , Feb. 1, 2016  Today, the ... Association (AHA) announced plans to develop a first of ... computing power of IBM Watson. In the first application ... AHA, IBM (NYSE: IBM ), and Welltok will ... and health assessments with cognitive analytics, delivered on Welltok,s ...
(Date:1/25/2016)... , Jan. 25, 2016   Unisys Corporation (NYSE: ... at John F. Kennedy (JFK) International Airport, New York ... (CBP) identify imposters attempting to enter the United ... belong to them. pilot testing of the system ... at three terminals at JFK during January 2016. --> ...
Breaking Biology News(10 mins):